Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance of its Investigational New Drug (IND) application to initiate a randomized, double-blind, placebo-controlled Phase 2 trial of Lucid-MS in people with multiple sclerosis. The milestone, highlighted in BioMedWire editorial coverage, positions the company to begin its first clinical testing of the drug candidate in MS patients and signals a potential shift in how the disease is treated.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (PAD2). Unlike standard MS therapies that broadly suppress the immune system, Lucid-MS aims to target demyelination—the underlying mechanism of MS—by preventing and reversing myelin degradation. The approach could offer a more direct way to address the progressive nerve damage that drives disability in MS patients.
The editorial noted that Lucid-MS previously completed Phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability. Those results support advancing the drug into a patient population, where the Phase 2 trial will evaluate both safety and preliminary efficacy signals. Quantum BioPharma is also collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on a parallel research effort involving a PET imaging tracer designed to quantify demyelination. That tracer could provide an objective biomarker for measuring treatment response, an important tool for assessing disease-modifying therapies.
Analyst attention has followed the regulatory progress. Rodman & Renshaw initiated coverage of Quantum BioPharma with a Buy rating and an $8 price target, according to the editorial. The coverage underscores investor interest in the company’s pipeline as it prepares Lucid-MS for its first clinical testing in people with MS. For a biopharmaceutical company at this stage, FDA clearance to proceed with a Phase 2 trial reduces a major regulatory risk and provides a clearer timeline for potential clinical data.
The editorial also placed Quantum BioPharma alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology and neurological diseases. The comparison highlights the competitive landscape for MS and neurodegenerative treatments, where companies are pursuing diverse mechanisms to address unmet needs. Quantum BioPharma’s focus on remyelination and demyelination sets it apart from immunosuppressive approaches and could complement existing therapies if successful.
For investors and patients, the FDA clearance matters because it moves Lucid-MS from preclinical and early safety testing into a patient-focused trial that can generate evidence of clinical benefit. A positive Phase 2 result would validate the PAD2 inhibition strategy and could attract partnership or licensing interest. The collaboration with Harvard-affiliated researchers also adds scientific credibility and may accelerate the development of imaging tools that support future trials.
Quantum BioPharma’s broader portfolio includes UNBUZZD(TM) and a retained ownership stake in Unbuzzd Wellness Inc., but its lead asset remains Lucid-MS. The company’s ability to execute the Phase 2 trial and report data will be a key catalyst. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For the full press release, visit https://ibn.fm/cwPHa.
